VANCOUVER, Dec. 20, 2013 /CNW/ - iCo Therapeutics (TSXV: ICO) (OTCQX:
ICOTF), announced that its common shares will begin trading today on
OTCQX International, a segment of the OTCQX marketplace in the U.S.,
under the symbol "ICOTF." iCo's common shares will also continue to
trade on the TSX Venture Exchange under the symbol "ICO".
iCo expects to benefit from trading on OTCQX by gaining greater exposure
and increasing liquidity in the United States, the location of all
clinical sites for its ongoing Phase 2 iDEAL study for diabetic macular
"We look forward to increasing awareness of the Company's ongoing
clinical developments and progress in the United States, the single
most important biotechnology investor market globally, by trading on
the OTCQX marketplace," said Andrew Rae, President & CEO of iCo
OTCQX International, a segment of the OTCQX marketplace, is reserved for
high-quality non-U.S. companies that are listed on a qualified
international exchange and provide their home country disclosure to
U.S. investors. U.S. investors can find current financial disclosures
and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
Troutman Sanders LLP will serve as iCo Therapeutics' Principal American
Liaison ("PAL") on OTCQX, responsible for providing professional
guidance on OTCQX requirements and U.S. federal securities laws.
About OTC Markets Group Inc.
OTC Markets Group Inc. operates Open, Transparent and Connected
financial marketplaces for 10,000 U.S. and global securities. Through
its OTC Link® ATS, they directly link a diverse network of
broker-dealers that provide liquidity and execution services for a wide
spectrum of securities. The company organizes these securities into
marketplaces to better inform investors of opportunities and risks -
OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The
Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®,
The Open Marketplace with Variable Reporting Companies. OTC Markets
Group's data-driven platform enables investors to easily trade through
the broker of their choice at the best possible price and empowers a
broad range of companies to improve the quality and availability of
information for their investors. To learn more about OTC Markets
Group, visit www.otcmarkets.com.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for new
or expanded use indications. The company has exclusive worldwide rights
to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and
iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2
clinical studies for DME. With Phase 2 clinical history, iCo-008 is
targeted for the treatment of keratoconjunctivitis and wet age-related
macular degeneration. In addition, iCo holds worldwide rights to an
oral drug delivery platform. The first platform candidate is the Oral
Amp B Delivery system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO" and the OTCQX under the symbol
"ICOTF". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will," and similar references to future periods. Such statements
involve known and unknown risks, uncertainties and other factors that
may cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on iCo's current
beliefs as well as assumptions made by and information currently
available to iCo and relate to, among other things, anticipated
financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are based only on information currently available to
iCo and speak only as of the date of this press release. Due to risks
and uncertainties, including the risks and uncertainties identified by
iCo in its public securities filings and on its website, actual events
may differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
SOURCE: iCo Therapeutics Inc.
For further information:
Mr. John Meekison, CFO
604-602-9414 x 224
Michael Moore, Investor Relations